CA2447023A1 - Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques - Google Patents

Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques Download PDF

Info

Publication number
CA2447023A1
CA2447023A1 CA002447023A CA2447023A CA2447023A1 CA 2447023 A1 CA2447023 A1 CA 2447023A1 CA 002447023 A CA002447023 A CA 002447023A CA 2447023 A CA2447023 A CA 2447023A CA 2447023 A1 CA2447023 A1 CA 2447023A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
seq
arg
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002447023A
Other languages
English (en)
Inventor
Edwin L. Madison
Joseph Edward Semple
George P. Vlasuk
Scott Jeffrey Kemp
Mallareddy Komandla
Daniel Vanna Siev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2447023A1 publication Critical patent/CA2447023A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des conjugués, des compositions et un procédé de traitement, de prévention, ou d'amélioration d'un ou des symptômes des maladies associées à la protéase des surfaces cellulaires, y compris les maladies associées à la sérine protéase membranaire, à l'activateur du plasminogéne de type urokinase, ou à l'endothéliase. Les conjugués utilisés dans les compositions et procédés sont des conjugués peptidiques qui contiennent des agents thérapeutiques, y compris des agents cytotoxiques.
CA002447023A 2001-05-23 2002-05-23 Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques Abandoned CA2447023A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29326701P 2001-05-23 2001-05-23
US60/293,267 2001-05-23
PCT/US2002/016819 WO2002095007A2 (fr) 2001-05-23 2002-05-23 Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques

Publications (1)

Publication Number Publication Date
CA2447023A1 true CA2447023A1 (fr) 2002-11-28

Family

ID=23128397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002447023A Abandoned CA2447023A1 (fr) 2001-05-23 2002-05-23 Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques

Country Status (5)

Country Link
EP (1) EP1545572A4 (fr)
JP (1) JP2005518332A (fr)
KR (1) KR20040004642A (fr)
CA (1) CA2447023A1 (fr)
WO (1) WO2002095007A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1544304A4 (fr) * 2002-07-31 2006-05-10 Astellas Pharma Inc Serine protease
JP5335191B2 (ja) 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
EP1831370A4 (fr) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
KR101393946B1 (ko) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US7772266B2 (en) 2006-02-15 2010-08-10 Dendreon Corporation Small-molecule modulators of TRP-P8 activity
CN101420942B (zh) 2006-02-15 2014-03-12 登德雷恩股份有限公司 Trp-p8活性的小分子调节剂
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
KR101778174B1 (ko) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system
CN103069555B (zh) 2010-08-18 2016-10-26 独立行政法人产业技术综合研究所 有机半导体薄膜以及有机半导体单晶薄膜的制造方法
EP2814807A4 (fr) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Antibiotiques à peptide linéaire
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3932935A1 (fr) * 2020-06-29 2022-01-05 Centre National de la Recherche Scientifique Peptides antibactériens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1161266A4 (fr) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, protease de la serine, et son utilisation
WO2001036604A2 (fr) * 1999-11-18 2001-05-25 Corvas International, Inc. Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
EP1263473A2 (fr) * 2000-03-15 2002-12-11 Bristol-Myers Squibb Pharma Company Medicaments antineoplastiques cibles pouvant etre clives par la peptidase et utilisation therapeutique de ces medicaments
CA2451188A1 (fr) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Ciblage cellulaire faisant appel a la reconnaissance des formes exponentielle, compositions, procedes et applications anticancereuses
WO2003037326A1 (fr) * 2001-10-29 2003-05-08 Corvas International, Inc. Synthese en phase solide de chimiotheques
JP2006503545A (ja) * 2002-02-14 2006-02-02 ラター， ウィリアム ジェイ． 処置される宿主における切断についてのキメラ分子
AU2003269880A1 (en) * 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10450286B2 (en) 2013-03-13 2019-10-22 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10457655B2 (en) 2013-03-13 2019-10-29 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10472342B2 (en) 2013-03-13 2019-11-12 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10800750B2 (en) 2013-03-13 2020-10-13 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10995078B2 (en) 2013-03-13 2021-05-04 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11267805B2 (en) 2018-10-29 2022-03-08 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone

Also Published As

Publication number Publication date
KR20040004642A (ko) 2004-01-13
EP1545572A2 (fr) 2005-06-29
JP2005518332A (ja) 2005-06-23
WO2002095007A2 (fr) 2002-11-28
WO2002095007A3 (fr) 2005-05-06
EP1545572A4 (fr) 2006-04-12

Similar Documents

Publication Publication Date Title
CA2447023A1 (fr) Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques
US20040001801A1 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
US9775913B2 (en) Method of site specific activation of an antibody by a protease
JP3481948B2 (ja) 新規ペプチド
KR100379351B1 (ko) 신규한펩타이드
EP1007696B1 (fr) Proteines chimeres specifiques du recepteur il-13 et utilisation de ces dernieres
JP3607201B2 (ja) Ｆａｐ活性化抗腫瘍性化合物
US7947289B2 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
WO2021136475A1 (fr) Conjugué de médicament et ses utilisations
US6391305B1 (en) Conjugates useful in the treatment of prostate cancer
WO1998008957A1 (fr) Compositions et procedes pour le ciblage specifique de tumeurs
JP2003526683A (ja) ペプチダーゼ切断可能な標的抗新生物薬およびそれらの治療への使用
KR20000052970A (ko) 전립선암 치료에 유용한 접합체
US8450280B2 (en) Activation of peptide prodrugs by hK2
IL125771A (en) Recombinant ribonuclease proteins
AU7432196A (en) Conjugates useful in the treatment of benign prostatic hyperplasia
Nichifor et al. Macromolecular prodrugs of 5-fluorouracil. 2: Enzymatic degradation
AU2002312119A1 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
CA2245804C (fr) Proteines de ribonuclease de recombinaison
AU714288B2 (en) Novel peptides
CN1242708A (zh) 用于治疗前列腺癌的偶联物
CA2234763A1 (fr) Conjugues utiles pour traiter l'adenome prostatique benin

Legal Events

Date Code Title Description
FZDE Dead